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Background: Vertebral fractures are the most frequent outcome in osteoporosis and may result in back pain with functional
limitations and diminished quality of life.
Objectives: Evaluate the risk of developing new or worsening back pain during treatment with teriparatide [rhPTH (1-34),
TPTD] or control + 30 months of additional follow up in patients with osteoporosis.
Methods: All four TPTD trials with posttreatment follow-up were included in our analyses: two placebo controlled trials,
1,2
 one
alendronate 10 mg daily comparator trial,
3
 and one study of hormone replacement therapy (HRT) versus HRT plus TPTD.
4
During follow-up, patients were allowed to receive other osteoporosis treatments. Back pain was defined as either new or
worsening in severity after the initiation of study drug through the end of posttreatment follow-up. The interaction of treatment
and study in a multivariate Cox proportional hazards model was used to assess the heterogeneity of results among studies and
to estimate the relative risk of back pain after adjusting for other osteoporosis drug use following discontinuation of TPTD.
Results: Findings were not statistically heterogeneous among trials (P = 0.66) and there were no differences between groups
administered TPTD20 or 40 mcg/day doses (P = 0.31). Therefore, placebo, HRT, and alendronate groups were pooled as a
control group and compared with pooled TPTD groups. Relevant data are listed in table below. Overall, patients in the pooled
TPTD group had reduced risk for any back pain, moderate or severe back pain, and severe back pain compared with pooled
control from initiation of study drug through the end of follow-up. A sensitivity analysis showed that the results were consistent
among trials and robust to the removal of each individual trial from the meta-analysis.
Endpoint Group N Cases Patient-years Rate (per 100 RR (95% C.I.)
at risk patient-yrs)
Any back pain Control 691 203 2187.2 9.28
TPTD 1222 285 4157.2 6.86 0.73 (0.61-0.87)
Moderate/severe Control 691 144 2340.8 6.15
back pain TPTD 1222 196 4354.9 4.50 0.72/ (0.58-0.89)
Severe back pain Control 691 45 4761.8 1.73
TPTD 1222 33 2607.9 0.69 0.39P (0.25-0.61)
Conclusion: The results demonstrate reduced back pain risk in patients with osteoporosis treated with teriparatide and then
followed for 30 additional months in four clinical trials.
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